Kazia Therapeutics (KZIA) Liabilities and Shareholders Equity (2009 - 2025)

Kazia Therapeutics has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $46.7 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 298.6% year-over-year to $46.7 million; the trailing twelve-month figure through Dec 2025 stood at $76.5 million (up 26.29% YoY), and the FY2025 full-year result was $3.9 million, down 72.72% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $46.7 million, up from $3.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $46.7 million in Q4 2025, with the low at $3.9 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $23.1 million across 5 years, with a median of $18.5 million in 2022.
• The largest YoY upside for Liabilities and Shareholders Equity was 298.6% in 2025 against a maximum downside of 72.72% in 2025.
• Kazia Therapeutics' Liabilities and Shareholders Equity stood at $32.5 million in 2021, then plunged by 43.8% to $18.3 million in 2022, then slipped by 13.21% to $15.9 million in 2023, then dropped by 26.21% to $11.7 million in 2024, then surged by 298.6% to $46.7 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $46.7 million (Q4 2025), $3.9 million (Q2 2025), and $11.7 million (Q4 2024), per Business Quant data.